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Multiple myeloma (MM) arises from malignant immunoglobulin
(Ig)-secreting plasma cells and remains an incurable, often lethal
disease despite therapeutic advances. The unfolded-protein re-
sponse sensor IRE1α supports protein secretion by deploying a kinase–
endoribonuclease module to activate the transcription factor XBP1s.
MM cells may co-opt the IRE1α–XBP1s pathway; however, the val-
idity of IRE1α as a potential MM therapeutic target is controversial.
Genetic disruption of IRE1α or XBP1s, or pharmacologic IRE1α kinase
inhibition, attenuated subcutaneous or orthometastatic growth of
MM tumors in mice and augmented efficacy of two established
frontline antimyeloma agents, bortezomib and lenalidomide.
Mechanistically, IRE1α perturbation inhibited expression of key
components of the endoplasmic reticulum-associated degradation
machinery, as well as secretion of Ig light chains and of cytokines
and chemokines known to promote MM growth. Selective IRE1α
kinase inhibition reduced viability of CD138+ plasma cells while
sparing CD138− cells derived from bone marrows of newly diag-
nosed or posttreatment-relapsed MM patients, in both US- and
European Union-based cohorts. Effective IRE1α inhibition preserved
glucose-induced insulin secretion by pancreatic microislets and vi-
ability of primary hepatocytes in vitro, as well as normal tissue
homeostasis in mice. These results establish a strong rationale
for developing kinase-directed inhibitors of IRE1α for MM therapy.
multiple myeloma | endoplasmic reticulum stress | unfolded protein
response | inositol-requiring enzyme 1 | kinase inhibitors
Multiple myeloma (MM) is the second most common humanhematologic cancer. It carries a lifetime risk of 0.7% and
occurs mainly in older individuals. MM is caused by bone marrow
infiltration by malignant, monoclonal immunoglobulin (Ig)-secreting
plasma cells (1). Despite significant therapeutic advances—including
proteasome inhibitors (PIs), immunomodulatory agents (IMiDs),
and anti-CD38 antibodies—MM remains mainly incurable, with ac-
quired resistance to all available agents, and a 5-y survival rate of 49%
(2). Considering the growth of aging populations in many countries,
there is an urgent unmet need for development of novelMM therapies.
The endoplasmic reticulum (ER) ensures precise folding of
newly synthesized secretory proteins. Upon elevated cellular
demand for protein secretion—for example, when mature B cells
differentiate into Ig-secreting plasma cells—insufficient ER ca-
pacity causes accumulation of unfolded proteins (UPs) in the ER
lumen. This activates a sensing–signaling network dubbed the
UP response (UPR) to orchestrate ER adaptation and reestablish
homeostasis (3–6). The mammalian UPR employs three pivotal
ER-resident transmembrane sensors: inositol-requiring enzyme
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1 α (IRE1α), protein kinase-like ER kinase (PERK), and acti-
vating transcription factor-6 (ATF6). UP detection by the ER-
luminal domain of each sensor engages the cytoplasmic moiety
to adjust the ER’s protein-folding, secretory, and degradative
capacities and alleviate ER stress. If adaptation fails and stress
becomes overwhelming, the UPR triggers apoptosis (7). Conserved
from yeast to primates, IRE1α harbors lumenal, transmembrane,
and cytosolic regions: The cytoplasmic part contains a serine/
threonine kinase domain and a tandem endoribonuclease (RNase)
module (8, 9). IRE1α activation involves oligomerization, kinase
transautophosphorylation, and RNase activation (9–12). The RNase
cleaves the mRNA encoding unspliced X-box protein 1 (XBP1u),
removing a 26-nucleotide intron, and triggering RtcB -mediated
ligation of spliced XBP1 (XBP1s) (3–5, 13). The XBP1s protein
acts as a transcription factor that stimulates multiple genes in-
cluding chaperones and disulfide isomerases that facilitate
protein folding (14–16). XBP1s also induces key components
of ER-associated degradation (ERAD), which promotes retro-
translocation of UPs into the cytoplasm, followed by their
ubiquitination and proteasomal disposal (14, 17). An alternative
IRE1α activity—termed regulated IRE1α-dependent decay
(RIDD)—cleaves ER-associated mRNAs to abate translational
load (18, 19) and suppress apoptosis (20, 21).
Because plasma–cell differentiation requires IRE1α and XBP1s
(22–24), and because cancer cells often co-opt normal stress-
response pathways to support malignant growth in hostile micro-
environments (25), it has been proposed that the IRE1α–XBP1s
pathway may represent a therapeutically useful vulnerability in
MM (26–28). Supporting this hypothesis, transgenic expression of
XBP1s in B cells drove MM-like pathology in mice (29), and high
XBP1s levels correlated with worse prognosis in MM patients
(30). XBP1s depletion by short hairpin RNAs (shRNAs) attenu-
ated growth of certain MM cell lines in vitro, and small-molecule
inhibition of IRE1α’s RNase with salicylaldehyde compounds
modestly attenuated human MM xenograft growth in mice (31,
32). Standard-of-care agents such as PIs are effective in MM
therapy likely because their inhibition of the 26S proteasome
creates a backlog of ERAD substrates that cannot be efficiently
degraded, thereby exacerbating ER stress (33). However, lower
XBP1s levels in MM cells correlated with PI resistance (33, 34).
Furthermore, although IRE1α kinase inhibition blocked XBP1s
production, it failed to attenuate MM cell growth under standard
tissue culture conditions in vitro (35). A significant caveat of
salicylaldehyde-based IRE1α RNase inhibitors is that the selectivity
of such compounds for IRE1α is difficult to ascertain; indeed, re-
cent work reveals that one of these compounds acts as an antioxi-
dant due to off-target activity (36). In addition, because XBP1s
depletion drives hyperphosphorylation of IRE1α (20, 37), alterna-
tive, XBP1s-independent IRE1α functions—for example, activation
of c-Jun N-terminal kinase (JNK) (38)—also may impact MM cells.
Whether IRE1α can be targeted effectively and safely via its kinase
domain to inhibit MM tumor growth under conditions that more
faithfully represent this disease remains an open question.
Our results demonstrate that the IRE1α–XBP1s pathway plays a
critical role in supporting MM cell growth in vitro in 3D culture set-
tings, as well as in vivo in subcutaneous (s.c.) as well as orthometastatic
tumor xenografts. Furthermore, selective small-molecule IRE1α kinase
inhibition reduced viability of malignant MM cells in patient-derived
bone marrows yet spared accompanying normal cells; it also pre-
served insulin secretion by pancreatic microislets and viability of
primary hepatocytes in vitro and was well tolerated at therapeutically
effective doses in mice. Together, these findings provide a compel-
ling rationale for targeting IRE1α via its kinase domain in MM.
Results
Depletion of IRE1α by shRNAs Attenuates 3D Growth of MM Cell
Lines. Interrogation of the cancer cell line encyclopedia (CCLE)
RNA sequencing (RNAseq) dataset (Broad Institute) demonstrated
that MM cell lines express higher messenger RNA (mRNA) levels
of IRE1α than all other cancer types (SI Appendix, Fig. S1A).
Further analysis of 12 human MM cell lines by immunoblot (IB)
revealed abundant IRE1α protein, often in conjunction with de-
tectable XBP1s protein (Fig. 1A), suggesting frequent IRE1α–
XBP1s pathway activation inMM cells. To investigate the importance
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Fig. 1. Expression of IRE1α in MM cell lines and ef-
fect of its depletion on spheroid 3D growth. (A)
Twelve human MM cell lines were analyzed by im-
munoblot (IB) for protein levels of IRE1α and XBP1s.
(B–F) KMS-11, OPM-2, and RPMI-8226 MM cells were
stably transfected with a plasmid encoding doxycycline
(Dox)-inducible shRNAs against IRE1α together with a
plasmid encoding mCherry. Cells were incubated in
the absence or presence of Dox (0.5 μg/mL) for 3 d,
seeded on ultralow adhesion (ULA) plates, centrifuged
to form single spheroids, and analyzed by IB for in-
dicated proteins (B) or for growth based on mCherry
fluorescence using an Incucyte instrument. (C–E, Lower)
Representative images of indicated MM cells grown as
single spheroids in ULA plates. (Scale bars, 800 μm.)
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of IRE1α for MM cell growth, we first used a doxycycline (Dox)-
inducible shRNA-based knockdown approach. As expected, Dox-
driven anti-IRE1α shRNA induction markedly decreased IRE1α
and XBP1s protein levels in KMS-11, OPM-2, and RPMI-
8226 MM cells (Fig. 1B). Importantly, Dox-induced IRE1α de-
pletion profoundly inhibited proliferation of these three cell lines
upon 3D growth as single spheroids on ultralow attachment (ULA)
plates, as evident by fluorescence imaging (Fig. 1 C–E). In contrast,
Dox treatment of the parental KMS-11 cells did not alter growth
(SI Appendix, Fig. S1 B and C). IRE1α knockdown also inhibited
3D growth of KMS-11 cells as multiple spheroids on Matrigel, as
determined via an Incucyte S3 instrument (SI Appendix, Fig. S1 D
and E). While Dox treatment did not affect viability, as measured
by CellTiter-Glo, of parental KMS-11 cells cultured on Matrigel,
Dox-induced IRE1α depletion led to a substantial loss of viability
(SI Appendix, Fig. S1 F–H). Thus, three genetically diverse MM cell
lines (39) displayed significant dependence on IRE1α for 3D
growth—a modality that more faithfully reflects in vivo tumor set-
tings than the conventional 2D culture used in earlier work (35).
Genetic Disruption of IRE1α or XBP1s Attenuates Growth of s.c.
Human MM Xenografts. We next disrupted IRE1α in KMS-11
cells using CRISPR/Cas9 gene editing. In contrast to parental IRE1α
wild-type (WT) KMS-11 cells, 3 independent IRE1α knockout
(KO) clones showed a complete absence of IRE1α protein and
failed to up-regulate XBP1s in response to the ER stressor
thapsigargin (Tg) (SI Appendix, Fig. S2A). Upon s.c. injection into
C.B-17 SCID mice, parental IRE1α WT KMS-11 cells formed
readily palpable tumors that reached a mean volume of ∼500 mm3
by 29 d; in contrast, all 3 IRE1α KO clones failed to sustain ap-
preciable tumor growth (Fig. 2A and SI Appendix, Fig. S2B).
Importantly, reconstitution of IRE1α KO cells with WT IRE1α
(WT RIRE1α) rescued tumor growth, whereas transfection with a
kinase-dead D688N mutant (KD RIRE1α) failed to do so (Fig. 2B
and SI Appendix, Fig. S2 C and D). Thus, s.c. establishment and
growth of KMS-11 MM xenografts in mice requires IRE1α and
depends on its kinase function.
To examine the relative importance of XBP1s for MM tumor
growth in vivo, we disrupted the XBP1 gene by CRISPR/Cas9 in
KMS-11 cells. Similar to the IRE1α KO clones, two independent
XBP1 KO clones failed to grow appreciably upon s.c. injection into
C.B-17 SCID mice, while parental IRE1α WT cells formed tumors
as expected (Fig. 2C and SI Appendix, Fig. S2E). Thus, in vivo growth
of KMS-11 tumor xenografts requires the IRE1α–XBP1s pathway.
To ascertain whether IRE1α depletion alone, or its com-
bination with standard anti-MM therapies, affects growth of
preestablished tumors, we allowed s.c. implanted KMS-11 or
RPMI-8226 cells carrying Dox-inducible shRNAs against IRE1α
or nontargeting control (NTC) to form palpable tumors of
∼200 mm3 and then initiated treatment with Dox. While NTC
shRNA induction had no impact on tumor growth, IRE1α
knockdown substantially suppressed tumor progression, in con-
junction with a marked decrease in XBP1s protein levels; this led
to 61% tumor-growth inhibition (TGI) in KMS-11 and 70% TGI
in RPMI-8226 xenografts (Fig. 2 D and E and SI Appendix, Fig.
S2 F–J). Furthermore, treatment in the KMS-11 model with the
maximum tolerated dose (MTD) of the PI bortezomib led to
54% TGI, while the combination of IRE1α knockdown and
bortezomib treatment afforded 91% TGI (P < 0.05 compared
with IRE1α knockdown alone) (Fig. 2D and SI Appendix, Fig.
S2G), indicating strong tumor attenuation. Similarly, treatment
in the RPMI-8226 model with the MTD of the IMiD lenalido-
mide led to 61% TGI, while combination of IRE1α knockdown
and lenalidomide administration achieved 110% TGI (P < 0.01
compared with IRE1α knockdown alone) (Fig. 2E and SI Ap-
pendix, Fig. S2H), indicating tumor regression. Together, these
results show that genetic disruption of IRE1α markedly inhibits
initiation and progression of MM tumor xenografts and increases
sensitivity to established anti-MM agents. Thus, perturbation of IRE1α
has significant potential to enhance the efficacy of MM therapy.
To explore mechanistically how disruption of IRE1α inhibits
tumor growth, we examined the regulation of genes that encode
key ERAD mediators (14, 17). IRE1α or XBP1 KO in KMS-11
cells attenuated in vitro Tg-induced mRNA expression of the E3
ubiquitin ligase SYVN1, the E2 ubiquitin-conjugating enzyme
UBE2J1, and factors required for the recognition and extraction
of terminally misfolded proteins from the ER, namely EDEM1,
DERL2, VIMP, DNAJC10, and ERLEC1 (Fig. 2F). Similarly,
IRE1α knockdown in RPMI-8226 cells reduced the constitutive
mRNA levels of these ERADmachinery genes (Fig. 2G). We next
examined the secretion of Ig light chains. IRE1α KO via CRISPR/
Cas9 or knockdown via anti-IRE1α shRNA, but not anti-NTC
shRNA, significantly attenuated secretion of Ig light chains by
KMS-11 and RPMI-8226 cells and increased intracellular re-
tention of light chain in the latter cells (Fig. 2 H and I and SI
Appendix, Fig. S2 K–M). Furthermore, IRE1α depletion in RPMI-
8226 cells both in vitro and in vivo inhibited secretion of several
cytokines, that is, vascular endothelial growth factor (VEGF),
interleukin (IL)-6, IL-10, and IL-1α, as well as the chemokines IL-8
(CXCL8) and interferon-inducible protein (IP)-10 (CXCL10)
(Fig. 2J and SI Appendix, Fig. S2N). Interestingly, IRE1 KO did
not significantly alter ER morphology in xenografted KMS-11
tumor cells, suggesting that ER ultrastructural organization
does not depend on IRE1α in these cells (SI Appendix, Fig. S2O).
The perturbation of both ERAD and protein secretion in MM
cells lacking IRE1α may compromise their growth in vivo (23, 40).
Small-Molecule Inhibition of IRE1α Kinase Attenuates Growth of s.c.
and Orthometastatic Human MM Xenografts. Next, we investigated
whether pharmacologic inhibition of IRE1α could recapitulate
the impact of genetic disruption on MM tumor growth. Because
XBP1s depletion through direct IRE1α RNase inhibition can
lead to hyperphosphorylation of the kinase domain (20, 41), we
chose to block IRE1α further upstream, at the kinase level. To
test whether IRE1α autophosphorylation controls RNase acti-
vation in MM cells, we reconstituted KMS-11 IRE1α KO cells
with cDNA expression plasmids encoding WT (WT RIRE1α) or
mutant variants of IRE1α enzymatically deficient in kinase activity
(D688N, KD RIRE1α) or in autophosphorylation on the kinase-
activation loop (S724A S726A S729A triple mutant, PD RIRE1α).
Upon ER stress, cells expressing WT IRE1α, but not the KD or
PD mutants, displayed increased production of XBP1s at the
protein and mRNA levels (Fig. 3A). Thus, disruption of either
the kinase function or the autophosphorylation sites of IRE1α in
MM cells blocks RNase activation and XBP1s production. This
finding is consistent with the failure of KD RIRE1α to rescue in
vivo growth of KMS-11 tumor xenografts (Fig. 2B).
Harrington et al. (35) identified kinome-selective inhibitors of
IRE1α kinase, including compounds 16 and 18 (Fig. 3B). We
synthesized both molecules and confirmed their binding to a
recombinant IRE1α protein comprising the kinase and RNase
domains, and their ability to inhibit its RNase activity toward a
synthetic XBP1-based RNA substrate, as well as cellular IRE1α
activity measured by an XBP1s-luciferase reporter assay (SI
Appendix, Fig. S3A) (11, 24). We compared the kinase selectivity
of these compounds by testing 220 kinases via KinomeScan.
Compound 18 displayed significantly better selectivity than 16,
with >70% inhibition of only 1 off-target kinase (JNK2), com-
pared with 7 for 16; another published IRE1α kinase inhibitor
called KIRA6 (42) was poorly selective, with >70% attenuation
of 64/220 kinases (Fig. 3B and SI Appendix, Fig. S3 A and B). Of
note, whereas compound 18 significantly attenuated spheroid
growth of KMS-11 cells on Matrigel, two different JNK-specific
inhibitors, JNK-IN-8 and SP600125, had only minor impact (SI
Appendix, Fig. S3C). Furthermore, mRNA expression of JNK2 in
RPMI-8226 and OPM-2 cells was relatively low compared with
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most other cell lines in the CCLE dataset (SI Appendix, Fig. S3D).
Therefore, any off-target inhibition of JNK2 by IRE1α kinase
inhibitors is unlikely to be functionally significant in these MM cell
lines. Quantitative PCR analysis demonstrated that 18 inhibited
constitutive IRE1α-mediated XBP1s production in RPMI-8226
cells, as well as Tg-induced XBP1s mRNA generation and RIDD
activity toward DGAT2 mRNA in KMS-11 cells, with half-maximal
inhibitory concentration of 82.5 and 76.5 nM, respectively (SI Ap-
pendix, Fig. S3 E and F).
To gain structural insight into the interaction of compound 18
with its target, we cocrystallized it with purified recombinant
IRE1α kinase–RNase protein and determined an X-ray structure
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2.3 cells were stably transfected with expression plasmids encoding wild-type (WT) IRE1α (WT RIRE1α) or kinase-dead (KD) D688N mutant IRE1α (KD RIRE1α),
injected SC into mice and monitored for tumor growth. (C) XBP1 was disrupted by CRISPR/Cas9 in KMS-11 cells. Parental or corresponding KO clones were
injected SC and monitored for tumor growth (mean tumor volume ± SEM). (D and E) KMS-11 (D) or RPMI-8226 (E) cells with Dox-inducible shRNAs against
IRE1α were inoculated SC and allowed to establish tumors. Mice were then randomized into treatment groups (n = 10 mice per group in D, n = 8 or 9 mice per
group in E): vehicle (sucrose), Dox in drinking water (D and E), bortezomib (BTZ), alone or with Dox (D), or lenalidomide (LEN), alone or with Dox (E), and
tumor growth was monitored. Individual mouse data are in SI Appendix, Fig. S2 G and H. (F) KMS-11 parental, IRE1α, or XBP1s KO cells were treated with
DMSO or Tg (100 nM) for 6 h and analyzed by RNAseq. Fold change in mRNA is shown for the indicated ERAD components. (G) Human free IgG κ light chains
were quantified in KMS11 parental or IRE1α KO Cl. 2.3 cell supernatants by ELISA 9 h after seeding. Fold change in secretion for equal cell numbers is shown.
(H) RPMI-8226 cells with Dox-inducible shRNAs against IRE1αwere incubated with Dox (0 or 1 μg/mL) for 3 d and analyzed by RT-qPCR. Fold change in mRNA is
shown for the indicated ERAD components. (I) RPMI-8226 cells with Dox-inducible shRNAs against NTC or IRE1α were incubated with Dox (0 or 1 μg/mL) for
3 d, equal number of cells seeded, and human free IgG λ light chains quantified in cell supernatants by ELISA 9 h later. (J) Mice bearing SC tumor xenografts of
RPMI-8226 cells with Dox-inducible shRNAs against IRE1α were treated with Dox in drinking water, and sera were collected and analyzed by luminex for fold
change in the concentrations of indicated cytokines and chemokines. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001. NS, not significant.
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at 2.20-Å resolution. Consistent with its ability to act as a kinase
inhibitor of IRE1α, 18 binds in the ATP docking site (Fig. 3C
and SI Appendix, Fig. S3G). The aminopyrimidine anchors at the
hinge and delivers the chloro-phenyl tail moiety to the kinase
back pocket. The sulfonamide forms hydrogen bonds with the
Asp, Phe, Gly (DFG) backbone in a DFG-in conformation and
accepts a hydrogen bond from the catalytic Lys residue, K599. The
Lys–Glu salt bridge typically seen in the active state of kinases is
absent in this structure, as K599 and E612 are separated by 5.4 Å.
The combined effects of back-pocket binding and salt-bridge
disruption may induce critical structural changes throughout the
cytoplasmic region that ultimately afford allosteric inhibition of
the RNase. This ligand-binding mode is reminiscent of the inter-
action of 16 with IRE1α (Protein Data Bank [PDB] ID code
4U6R) (35). However, the 1,4 substituted naphthyl linker of 18
pulls back from the kinase N-lobe by ∼1.0 Å compared with the
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Fig. 3. Importance of IRE1α kinase in RNase activation in growth of MM cell lines in 3D versus 2D. (A) KMS-11 IRE1α knockout (KO) cells (Cl. 2.3) were
transiently transfected with expression plasmids encoding wild-type IRE1α (WT RIRE1α), a “kinase-dead” D688N mutant of IRE1α (KD RIRE1α), or an
“autophosphorylation-deficient” S724A, S726A, S729A triple mutant of IRE1α (PD RIRE1α). Cells were then incubated in the absence or presence of thapsigargin
(Tg, 100 nM) for 3 h and analyzed either by IB for levels of the indicated proteins or by RT-qPCR for mRNA levels of XBP1s. (B) Chemical structures of
compounds 18 and 16 (35) and KIRA6 (42). (C) A close-up view of the crystal structure of 18 in complex with the kinase-RNase portion of IRE1α. The protein is
rendered in ribbons with key residues in the ligand-binding pocket shown as sticks. Water molecules near the ligand are shown in red spheres. Black dashed
lines indicate hydrogen bonding interactions. (D) Comparison between the cocrystal structures of 18 (colored in wheat and orange versus 16 (PDB ID code
4U6R, colored cyan and blue) bound to IRE1α. The C-terminal end of the αC-helix displays significant conformational changes between the two structures. (E)
KMS-11, OPM-2, and RPMI-8226 cells were seeded on standard tissue culture plates (2D) or ULA plates followed by centrifugation to form single spheroids
(3D). After 96 h, cells were lysed and analyzed by IB for indicated proteins. (F–H) Cells were seeded either in the 2D or 3D setting, treated for 150 h with
vehicle (DMSO) or compound 18 at the indicated concentrations, and analyzed for cell growth by cell confluence using an Incucyte instrument (F) or cell
viability using CellTiter-Glo 3D (G and H). **P ≤ 0.01, ***P ≤ 0.001.
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1,5 substituted naphthyl linker of 16. Further comparison reveals
that 18 displaces the C-terminal end of the Cα-helix to a greater
extent than does 16, where residue Y628 shows the most differ-
ence in side-chain conformation (Fig. 3D). Although we cannot
rule out that crystal packing may influence this, structural changes
in the Cα-helix may contribute to the improved selectivity of 18
against IRE1α. We therefore chose the latter molecule as a tool
for further studies.
We next investigated the effect of compound 18 on MM cells
growing on standard tissue culture plates (2D) compared with
ULA plates (3D). As a prelude, we examined the activation state
of the IRE1α pathway in cells growing in 2D or 3D. IB analysis of
KMS-11, OPM-2, and RPMI-8226 cells suggested elevated ac-
tivity of IRE1α in 3D versus 2D settings, evident by detectable
increases in IRE1α protein and/or phosphorylation and in
XBP1s levels (Fig. 3E). Importantly, whereas both compound 18
and the previously published IRE1α RNase inhibitor 4μ8c (43)
markedly inhibited 3D growth of all three cell lines, these in-
hibitors had much weaker impact on 2D growth (Fig. 3 F–H and
SI Appendix, Fig. S3 H–N). We obtained similar results with
three additional B-derived, nonmyeloma cancer cell lines that
expressed detectable baseline levels of IRE1α and XBP1s (SI
Appendix, Fig. S3 O–R), supporting the importance of IRE1α for
3D growth of such cells.
Next, we turned to investigate the effect of compound 18 on
growth of MM tumor xenografts in vivo. Upon intraperitoneal
(IP) injection at 30 mg/kg, once (QD) or twice (BID) per day, in
C.B-17 SCID mice, 18 achieved initial plasma concentrations of
4.3 μM and remained above 0.1 μM for ∼8 h (SI Appendix, Fig.
S4A). These data suggested potentially sufficient exposure to this
compound to attain significant, though perhaps incomplete,
IRE1α inhibition in vivo. Comparable to the effect of IRE1α
shRNA depletion, BID treatment of mice bearing preestablished
KMS-11 tumor xenografts with 18 led to a substantial reduction
in XBP1s protein, in conjunction with 51% TGI (Fig. 4A and SI
Appendix, Fig. S4 B and C). We next tested the effect of QD
administration of the compound on growth of OPM-2 tumor
xenografts; we observed 70% TGI, comparable to Dox-induced
shRNA-mediated knockdown of IRE1α (Fig. 4B and SI Appendix,
Fig. S4 D and E). Thus, pharmacologic IRE1α kinase inhibition
recapitulated the impact of shRNA-based IRE1α depletion on
growth of MM xenografts.
We then turned to a more stringent orthometastatic model of
MM, in which luciferase and mCherry double-labeled RPMI-8226
cells, injected into the tail vein of NSG mice, develop widespread
malignant disease with bone marrow involvement over a period of
6 wk (SI Appendix, Fig. S4F) (44). Treatment of mice bearing
established malignant disease with 18 over two subsequent weeks
led to a marked reduction in tumor burden, evident by diminished
luminescence (Fig. 4C): Whereas 3/3 control mice displayed tu-
mor progression over baseline, only 1/5 18-treated mice showed
tumor progression, while another 1/5 exhibited tumor stasis, and
3/5 showed substantial tumor regression. Thus, pharmacologic
inhibition of IRE1α kinase in vivo disrupts growth of MM xeno-
grafts not only in the s.c. setting but also in the more clinically
relevant orthometastatic bone marrow microenvironment.
IRE1α Kinase Inhibition Reduces Viability of Patient-Derived MM Cells
While Sparing Normal Cells. Cancer cell lines may acquire further
genetic or epigenetic alterations upon prolonged passage that
could diverge them from their primary source. Therefore, to gain
a more direct appraisal of the importance of IRE1α for primary
MM cell survival, we tested the effect of compound 18 on via-
bility of CD138+ plasma cells from the donated bone marrow or
peripheral blood of MM patients clinically treated in the United
States or the European Union (SI Appendix, Fig. S5A). Incuba-
tion with 18 led to marked reductions in viability of the malig-
nant CD138+ MM cells, but not the associated nonmalignant
CD138− cells, in the majority of cases (Fig. 5 A and B). In both
MM cohorts, samples from newly diagnosed patients as well as
subjects whose disease relapsed after 1 to 4 prior lines of therapy
showed dose-dependent sensitivity to 18 (Fig. 5 C and D).
Comparison of the impact of 18 and 4μ8c on an additional MM
bone marrow aspirate suggested greater loss of plasma-cell via-
bility with the former (SI Appendix, Fig. S5 B and C). Impor-
tantly, exposure to 18 did not reduce viability of CD138+ cells
from three nonmalignant bone marrow aspirates (Fig. 5E). Thus,
IRE1α kinase inhibition can selectively disrupt survival of pri-
mary malignant MM cells while sparing nonmalignant hemato-
poietic cells, including plasma cells. The impact on both naïve
and posttreatment-relapsed MM samples suggests that IRE1α
inhibition has the potential to provide clinical benefit across
several different lines of therapy.
We next turned to investigate whether pharmacologic IRE1α
kinase inhibition disrupts normal function of other cell types.
Inducible gene-knockout studies in mice have suggested that the
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Fig. 4. Small-molecule inhibition of IRE1α kinase attenuates s.c. and
orthometastatic growth of human MM xenografts in mice. (A) KMS-11 cells
stably transfected with doxycycline (Dox)-inducible shRNAs against IRE1α
were inoculated s.c. into C.B-17 SCID mice and allowed to establish tumors of
∼200 mm3. Mice were then randomized into the following groups (n =
15 per group): vehicle, Dox in the drinking water (0.5 mg/kg), or compound
18 (30 mg/kg) intraperitoneally (IP) twice per day (BID). Tumor growth was
monitored over 24 d. Individual tumor data are shown in SI Appendix, Fig.
S4C. (B) OPM-2 cells stably transfected with Dox-inducible shRNAs against
IRE1α were inoculated s.c. into C.B-17 SCID mice and allowed to establish
tumors of ∼160 mm3. Mice were then randomized (n = 14 per group) treated
as in A with either vehicle, Dox in the drinking water, or compound 18 IP
once per day and monitored for tumor growth over 11 d. Individual tumor
data are shown in SI Appendix, Fig. S4E. (C) RPMI-8226 cells expressing
plasmids encoding mCherry and luciferase were injected i.v. via the tail vein
of nonirradiated NOD/SCID/IL2rγ−/− mice and tumors were allowed to es-
tablish in the bone marrow over a period of 6 wk. Tumor burden was
monitored by in-life imaging of luminescence. After 6 wk, mice were
grouped out based on similar tumor burden, treated with vehicle (n = 3) or
compound 18 (30 mg/kg IP, BID, n = 5) for 2 wk, and analyzed for tumor
burden. One control mouse died during anesthesia and one treated mouse
was killed due to weight loss. Luminescence images of representative mice
are depicted on the left. The tumor burden of each mouse is shown as
percent tumor growth on day 14 (at the end of 8 wk) compared with day
0 of treatment (Tx, at the end of 6 wk). **P ≤ 0.01, ***P ≤ 0.001.
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IRE1α–XBP1s pathway may support insulin secretion by pancreatic
cells (45, 46) and homeostasis of hepatocytes (47). Therefore, we
first verified the ability of compound 18 to inhibit XBP1s induction
in human pancreatic islet 3D microtissues, which contain all of the
endocrine cell types and can retain viability and function in culture
for up to 4 wk (48). At 2.4 μM, 18 suppressed Tg-induced XBP1s
production to baseline levels (Fig. 6A), confirming effective IRE1α
pathway inhibition. Importantly, 18 did not decrease viability, nor
did it perturb glucose-stimulated insulin secretion even at higher
concentrations up to 7.5 μM (Fig. 6 B and C). We obtained similar
results with rat pancreatic microislets (SI Appendix, Fig. S6 A and
B). Furthermore, despite completely blocking tunicamycin-induced
XBP1s expression by primary human hepatocytes at 3 μM, treat-
ment with 18 did not impact hepatocyte viability at concentrations
up to 6 μM (Fig. 6 D and E). In addition to these in vitro experi-
ments, we performed a tolerability study of compound 18 in C.B-17
SCID mice by IP injection at 10, 30, or 100 mg/kg BID over 7 d.
Whereas some mice did not tolerate the 100 mg/kg dose, animals
administered up to 30 mg/kg completed the dosing period with only
a minor weight loss compared with vehicle-treated controls, along
with minimal changes in serum albumin and in the bone marrow
myeloid compartment. Some peritoneal inflammation was seen in
both vehicle- and 18-treated mice, likely due to the repeated IP
injections. There were no other compound-related changes in hema-
tology, serum chemistry, or organ weights; furthermore, there were no
gross or microscopic pathology findings overall, notably including in
secretory organs such as the pancreas and salivary glands (SI Ap-
pendix, Fig. S6C andD). In a separate study, dosing of 18 at 30 mg/kg
QD for 3 wk did not cause significant alterations in hepatic,
renal, and pancreatic endocrine functional markers in serum (SI
Appendix, Fig. S6E). Together, these results suggest that IRE1α
kinase inhibition can achieve effective MM tumor disruption
without overt negative effects on normal tissue homeostasis.
Discussion
MM cells may co-opt the IRE1α–XBP1s pathway to mitigate per-
sistent ER stress, caused by Ig production and a nutrient/oxygen-poor
bone marrow microenvironment (27). However, recent studies
have raised significant doubt concerning the validity of IRE1α as
a potential MM therapeutic target: Lowered levels of XBP1s
correlated with PI resistance in MM cells (49), and IRE1α kinase
inhibition blocked XBP1s yet did not affect MM cell viability in
2D culture (35, 49). Although work based on salicylaldehyde
small-molecule RNase inhibitors supported a protumorigenic
role of IRE1α in MM (31, 32), such compounds are highly protein-
reactive, and their selectivity versus off targets is difficult to confirm
(36). Direct loss-of-function studies specifically addressing the im-
portance of the kinase module of IRE1α for MM growth in vivo
have been lacking.
To interrogate the requirement of IRE1α for MM growth, we
employed a series of strategies to disrupt it at the gene, transcript,
or kinase level, in diverse model systems. Our in vitro studies
showed that IRE1α depletion by shRNAs markedly attenuates
growth of several MM cell lines in 3D spheroid settings—a scenario
that was not previously investigated in connection with IRE1α.
Consistent with this elevated dependency, MM cells growing in 3D
showed increased baseline activity of the IRE1α pathway compared
with 2D. In vivo, both IRE1α KO and XBP1s KO in KMS-11 MM
cells profoundly disrupted their ability to form s.c. tumor xenografts
in mice. Critically, reconstitution of WT but not kinase-dead IRE1α
into KO cells rescued tumor growth, validating the conclusion that
disrupted growth was specifically due to IRE1α kinase loss of
function. These findings demonstrate a crucial requirement of the
57
6 T
1
10
03
12
29
57
6 T
3
10
55 70
0
61
4 T
2
10
70
0
50
100
150
y
(
)
*** *** * *** *** ***
10
17
11
05
17
19
05
17
20
0
50
100
150
A
N1 N2 N3
0
50
100
150
y
NS
NS
NS
EC D
BUSA cohort EU cohort
USA cohort EU cohort USA cohort
NDx Relapsed NDx Relapsed
NDx Relapsed NDx Relapsed Normal
Vi
a
bi
lit
y 
(%
 
o
f v
e
hi
cl
e
)
Vi
ab
ili
ty
 
(%
 
o
f v
e
hi
cl
e)
CD138+ Vehicle
CD138+ 5 M Cpd 18
CD138+ 10 M Cpd 18
10
17
11
05
17
19
05
17
20
MM
49
07
17
39
0
50
100
150
CD138+ Vehicle
CD138+ Cpd 18
CD138-  Cpd 18
CD138- Vehicle
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possible due to insufficient sample size. NS, not significant. *P < 0.05, ***P ≤ 0.001.
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IRE1α pathway for in vivo MM growth, while other, kinase- or
XBP1s-independent functions of IRE1α such as RIDD or JNK
activation may be less important in the context of MM. IRE1α
depletion by shRNAs clearly inhibited the growth of preformed s.c.
KMS-11 and RPMI-8226 tumor xenografts, implicating IRE1α not
only in promoting tumor initiation but also progression. Remark-
ably, the extent of TGI was directly comparable between IRE1α
knockdown and the established frontline MM therapy agents bor-
tezomib or lenalidomide. Furthermore, combination of IRE1α
depletion with bortezomib or lenalidomide significantly increased
the extent of TGI compared with respective monotherapies. Mech-
anistically, IRE1α knockdown decreased mRNA expression of
multiple ERAD components known to be induced by XBP1s.
Moreover, it diminished the ability of MM cells to secrete Ig light
chains as well as several cytokines and chemokines, some of which
have previously been shown to support malignant plasma cell
growth in vitro and in vivo (1, 23, 33, 40). In contrast, IRE1α dis-
ruption did not significantly alter ER morphology. Together, these
results suggest that IRE1α inhibition has potential to provide sig-
nificant clinical benefit, either alone or in combination with other
MM therapies known to disrupt protein homeostasis (33, 50).
To further examine the requirement for IRE1α’s kinase moi-
ety, we first confirmed its importance for RNase activation by
mutational perturbation of the kinase catalytic core or its target
autophosphorylation sites. We then evaluated three compounds
that bind to IRE1α’s ATP docking site and exert allosteric in-
hibition of RNase activation (35, 42). One of these, compound
18, displayed an improved ability to displace the Cα helix in the
kinase domain and excellent selectivity toward IRE1α versus
220 other kinases. In keeping with the results of genetic IRE1α
disruption, 18 inhibited growth of MM cells in 3D settings more
substantially than in 2D. The IRE1α RNase inhibitor 4μ8c sim-
ilarly attenuated 3D growth of MM cells, confirming the in-
volvement of IRE1α. In mice, 18 displayed sufficient exposure
upon IP administration to enable marked inhibition of XBP1s
production in tumors. In concert, 18 significantly attenuated s.c.
growth of KMS-11 and OPM-2 xenografts. Thus, pharmacologic
inhibition of IRE1α via its kinase moiety recapitulated the im-
pact of genetic IRE1α disruption on MM tumor growth.
To address the importance of IRE1α in a more clinically rel-
evant MM microenvironment, we implemented an orthometa-
static model, in which malignant MM cells injected intravenously
(i.v.) home to the bone marrow to disseminate malignant dis-
ease. Treatment with 18 in this setting led to tumor stasis or
regression in most of the animals, compared with aggressive
tumor progression in the vehicle-treated controls. Thus, MM
cells require IRE1α kinase function in vivo to sustain advanced
malignant growth in the bone marrow.
Establishing the excellent kinase selectivity of compound 18
afforded a unique opportunity to examine more reliably the
impact of specific IRE1α inhibition on patient-derived MM cells.
Remarkably, the compound caused a substantial reduction in
viability of malignant CD138+ cells in the majority of MM patient
samples, including newly diagnosed tumors as well as tumors that
relapsed after 1 or more lines of prior therapy with clinically
established agents. In contrast, to its effect on malignant plasma
cells, 18 did not significantly reduce viability of accompanying
nonmalignant cells in the same MM samples; it also spared both
CD138+ plasma cells and CD138− cells in nonmalignant bone
marrow aspirates. Treatment with the IRE1α RNase inhibitor 4μ8c
also reduced viability of MM patient-derived CD138+ plasma cells,
further confirming the reliance of these cells on IRE1α. In pre-
clinical safety experiments, while 18 achieved complete XBP1s
suppression in pancreatic microislets, it disrupted neither viability
nor the capacity of these tissues to secrete insulin in response to
glucose challenge. Similarly, 18 did not impact viability of primary
human hepatocytes in vitro. In mice, at doses that effectively
inhibited tumor growth, 18 did not significantly alter normal ho-
meostasis of numerous tissues and organ systems examined, in-
cluding secretory cells. Taken together, these results suggest that
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Fig. 6. IRE1α kinase inhibition preserves survival and insulin secretion by pancreatic islet 3D microtissues and viability of primary hepatocytes. (A–C) Human
pancreatic islets were isolated, dissociated, replated in microtiter wells (1,000 cells per drop), and allowed to form 3D microtissues over 7 d. Microtissues (n =
5 per treatment) were then (A) treated for 24 h with either vehicle control (DMSO) or tunicamycin (Tm, 5 μg/mL) in addition to either vehicle (DMSO) or
compound 18, lysed, and then analyzed for XBP1s mRNA levels by RT-qPCR (%XBP1s mRNA is the ratio of XBP1s mRNA/(XBP1s mRNA+XBP1u mRNA); or (B
and C) incubated for 7 d in the presence of either vehicle (DMSO) or compound 18 and then (B) analyzed for cell viability by CellTiter-Glo; or (C) challenged
with glucose (16.7 mM) for 1 h and analyzed for insulin secretion by ELISA. (D and E) Human primary hepatocytes were treated for 8 h with either control or
Tm in addition to either vehicle or compound 18 and analyzed for XBP1s levels as above by RT-qPCR (D). Alternatively, hepatocytes were cultured for 48 h in
the presence of vehicle (DMSO) or compound 18 and analyzed for cell viability by CellTiter-Glo (E).
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malignant MM cells harbor an enhanced dependency on the
IRE1α–XBP1s pathway compared with nonmalignant cell types,
highlighting this pathway as a unique vulnerability that could be
clinically exploited to treat MM across multiple stages. Never-
theless, future testing of IRE1α inhibitors in human clinical trials
will necessitate the development of orally available compounds
and more comprehensive safety studies in suitable model organ-
isms. In addition, it would be interesting to investigate the effect of
such inhibitors on MM tumor growth in immunocompetent mice,
in light of recent evidence that disruption of XBP1s augments
antitumor immunity in syngeneic models of epithelial cancer (6).
In conclusion, our work provides definitive preclinical evi-
dence validating IRE1α as a potential therapeutic target for
MM. IRE1α may play an important role in augmenting malig-
nant growth of MM cells by enabling their adaptation to chronic
ER stress through elevated ERAD capacity. IRE1α may also
support the secretion of Ig light chains as well as cytokines and
chemokines that enable survival and growth of malignant MM
cells in their metabolically restrictive bone marrow microenvi-
ronment. Finally, while RNase inhibition of IRE1α also holds
promise, our findings provide proof of concept that the kinase
domain of IRE1α is likely to provide an effective and safe lever
for small-molecule inhibition of this unique dual-function en-
zyme. This work therefore establishes a compelling rationale to
develop clinical-grade kinase-based inhibitors of IRE1α for
MM therapy.
Materials and Methods
Detailed methods are provided in SI Appendix.
Cell Culture and Experimental Reagents. KMS-11, RPMI-8226, OPM-2, NCI-
H929, KMS-27, MOLP-8, LP-1, U266B1, UTMC-2, KMM-1, KMS28-PE, MOLP-
2, NU-DUL-1, OCI-LY18, and NALM-6 cells were obtained from ATCC, JCRB,
or DSMZ, authenticated by short tandem repeat profiles, and tested to ensure
they were mycoplasma-free within 3 mo of use. All cell lines were cultured in
RPMI1640 media supplemented with 10% (vol/vol) FBS (Sigma), 2 mM glu-
taMAX (Gibco), and 100 U/mL penicillin plus 100 μg/mL streptomycin (Gibco).
Thapsigargin (Sigma) was used at a concentration of 100 nM and tuni-
camycin (Sigma) at 5 μg/mL. Doxycycline was from Clontech. Compound 16/16,
compound 18/18 (35), 4μ8c (43), JNK-IN-8, and SP600125 (Sigma) were
dissolved in DMSO for cellular experiments and used at the indicated con-
centrations. Antibodies (Abs) for IRE1α (3294), β-actin (3700), and GAPDH
(5174) were from Cell Signaling Technology. Ab for detection of human IgG
light chains (709-005-149) was from Jackson ImmunoResearch. Abs for XBP1s
and pIRE1 (21) were generated at Genentech. Secondary antibody (711-035-
152) was from The Jackson Laboratory.
Two-Dimensional Proliferation Assays. For compound 18 and 4μ8c serial di-
lution studies, RPMI-8226 IRE1α sh7-5 and OPM-2 IRE1α sh9, NU-DUL-1, OCI-
LY18, and NALM-6 cells were plated in flat clear-bottom 96-well plates
(Corning) at 2.5 × 103 cells per well; KMS-11 IRE1α sh8-9 cells were seeded in
standard 6-well plates (Corning) at 1 × 105 cells per well. Compound 18 and
4μ8c were used at the indicated concentrations. After 150 h, cell viability of
RPMI-8226 IRE1α sh7-5 and OPM-2 IRE1α sh9, NU-DUL-1, OCI-LY18, and
NALM-6 cells was assessed using an ATP-consumption assay (CellTiter-Glo 3D;
Promega) and measured in a luminescence reader (Envision; PerkinElmer).
Cell confluency of KMS-11 IRE1α sh8-9 cells was measured using a real-time
imaging system (IncuCyte; Essen Bioscience). Frames were captured at 4-h
intervals using a 10× objective. Assays were run at least in triplicates.
Three-Dimensional Spheroid Proliferation Assays. For IRE1α knockdown ex-
periments, KMS-11 IRE1α sh8-9-mCherry, RPMI-8226 IRE1α sh7-5-mCherry,
and OPM-2 IRE1α sh9-mCherry cells were pretreated with 0.5 μg/mL Dox
for 3 d before plating 1 × 103 cells per well in ULA 96-well plates (Corning).
For compound 18 and 4μ8c serial dilution studies in this setting, KMS-11α
IRE1 sh8-9, RPMI-8226 IRE1α sh7-5 and OPM-2 IRE1α sh9, NU-DUL-1, OCI-
LY18, and NALM-6 cells cells (2.5 × 103 cells per well) were plated in ULA
96-well plates. Compound 18 and 4μ8c were used at the indicated concen-
trations. Single spheroids were formed by centrifugation (1,000 rpm) for
10 min according to the manufacturer’s protocol. Spheroids were imaged
using an IncuCyte instrument. Frames were captured at 4-h intervals using a
4× objective and red fluorescence or cell confluence was detected. After
150 h, cell viability of was assessed using CellTiter-Glo 3D.
For Matrigel assays, KMS-11 WT or IRE1α sh8-9 cells were pretreated with
0.5 μg/mL Dox for 3 d before plating 1 to 5 × 103 cells per well on 50 μL/well
of Matrigel (Corning) into 96-well plates according to the manufacturer’s
protocol. To test the impact of JNK inhibition compared with compound 18
in this setting, cells were seeded on Matrigel as described and then treated
with serial dilutions of 18, JNK-IN-8, or SP600125 as indicated. Multi-
spheroids were imaged using an IncuCyte S3 instrument (Essen Bioscience).
Frames were captured at 4-h intervals using a 10× objective and cell con-
fluency was detected, and then 150-h cell viability assessed using CellTiter-
Glo 3D. Cultures were maintained at 37 °C throughout and run at least in
triplicates. Values well were pooled and averaged across all replicates.
Human MM Samples. The effect of compound 18 on viability of MM or normal
cells was measured after treatment in ex vivo culture of bone marrow as-
pirates or blood samples from MM patients or from normal bone marrow
donors. All samples were deidentified before use in this study. For cell death
assays, mononuclear cells obtained after separation on Ficoll density gradient
were cultured in RPMI1640 media supplemented with 5% FCS and 3 ng/mL IL-6,
with the indicated concentrations of compound 18 or vehicle control
(DMSO) for 48 to 72 h. MM cells were then identified using CD138-PE staining
and cell death was assessed by the loss of CD138 staining as previously de-
scribed (51). MM or normal plasma cells were identified as CD19−, CD45−/dim,
CD38+, CD138+, and CD46+.
Pancreatic Islet 3D Microtissue Assays. Human and rodent 3D InSight pan-
creatic islet microtissues (InSphero AG) were generated from reconstituted
dispersed human or rat pancreatic islet cells in a modified manner as de-
scribed previously (48) retaining the composition of α, β, and δ cells repre-
sentative of normal endocrine pancreatic islets. Cells were plated in
microtiter wells (1,000 cells per drop) and allowed to form 3D microtissues of
∼120 μm in diameter over 7 d (n = 5 per treatment). Microtissues were in-
cubated for 7 d with serial dilutions of compound 18 or vehicle control
(DMSO) and then viability analyzed by CellTiter-Glo or insulin secretion an-
alyzed after glucose challenge (16.7 mM) for 1 h by ELISA.
Human Hepatocyte Experiments. Normal primary human hepatocytes (Millipore
Sigma) were cultured on collagen-coated 96-well plates and assays were per-
formed in serum-free hepatocyte incubation media. Hepatocytes were treated
with Tm (5 μg/mL) for 8 h in the presence of compound 18 or vehicle control
(DMSO) at the indicated concentration and analyzed for XBP1s levels by RT-
qPCR or cultured for 48 h in the presence of vehicle (DMSO) or 18 at the in-
dicated concentrations and analyzed for viability by CellTiter-Glo.
s.c. Xenograft Growth and Efficacy Studies. All procedures were approved by
and conformed to the guidelines and principles set by the Institutional An-
imal Care and Use Committee of Genentech and were carried out in an
Association for the Assessment and Accreditation of Laboratory Animal Care-
accredited facility.
For tumor growth studies, 10 × 106 KMS-11 parental, IRE1α KO or XBP1 KO
clones, or IRE1α KO +WT RIRE1α or +KD RIRE1α clones were suspended in
HBSS, admixed with 50% Matrigel to a final volume of 100 μL, and injected
s.c. in the right flank of 6- to 8-wk-old female C.B-17 SCID mice.
For efficacy studies, 10 × 106 KMS-11 NTC shRNA or IRE1α sh8-9, RPMI-
8226 NTC shRNA or IRE1α sh5-7, or OPM-2 IRE1α sh9 cells were prepared and
s.c. inoculated as outlined above. Tumors were monitored until they reached
a mean tumor volume of ∼150 to 300 mm3. For efficacy studies of IRE1
shRNA knockdown, animals were randomized into the following treatment
groups: 1) 5% sucrose water (provided in drinking water, changed weekly)
or 2) Dox (0.5 mg/mL, dissolved in 5% sucrose water, changed 3 times per
week). For efficacy studies of IRE1 shRNAs-mediated knockdown in combi-
nation with standard of care agents, bortezomib (Velcade; Millennium
Pharmaceuticals) or lenalidomide (Revlimid; Celgene Corp.), mice were ran-
domized into one of the following treatment groups: 1) vehicle (5% sucrose
water); 2) Dox; 3) bortezomib (0.75 mg/kg, 100 μL total, i.v., twice per week)
or lenalidomide (50 mg/kg, 100 μL total, IP, QD for five consecutive days),
respectively; or 4) combination of Dox plus bortezomib, or doxycycline plus
lenalidomide, respectively.
For compound 18 efficacy studies, animals were randomized into one of
the following treatment groups: 1) vehicle controls (35% PEG400 and 10%
EtOH in water, 100 μL total, IP, QD) and 5% sucrose water; 2) Dox; or 3)
compound 18 (30 mg/kg, 100 μL total, IP, QD or BID as indicated in figure
legends).
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Orthometastatic Xenograft Efficacy Studies. For the orthometastatic xeno-
graft model, 1 × 106 RPMI-8226-mCherry-Luc cells were injected i.v. via the
tail vein of nonirradiated 8-wk-old female NOD/SCID/IL2rγ−/− mice (NSG; The
Jackson Laboratory). The animals were imaged weekly under isoflurane
anesthesia 5 min after i.p. luciferin injection with 200 μL of 25 mg·mL−1
D-luciferin (Invitrogen) and imaged on a Photon Imager (BioSpace Laboratory).
During image acquisition, animals continued to receive anesthesia from a
nose-cone delivery system, while their body temperatures were maintained
on a thermostatically controlled platform. Photon counts per min per square
centimeter of observational area were calculated and compared using M3
Vision software (BioSpace Laboratory). After 6 wk mice were grouped out
into the following treatment groups: 1) vehicle control (100 μL total, IP, BID)
or 2) compound 18 (30 mg/kg, 100 μL total, IP, BID). After 14 d, mice were
killed by cervical dislocation and bones harvested for fluorescence imaging
using a Kodak In-Vivo FX system (Carestream Health Molecular Imaging) and
Carestream Molecular Imaging (MI) Software. Excitation and emission
wavelengths were fixed at 550 nm and 600 nm, respectively. Fluorescence
images were coregistered with X-ray images using the open-source software
Image J (https://imagej.nih.gov/ij/).
Statistics. All values are represented as arithmetic mean ± SD if not otherwise
indicated in the figure legends. Statistical analysis of the results was per-
formed by unpaired, two-tailed t test or ANOVA followed by an appropriate
post hoc analysis, including Bonferroni correction to compensate for multi-
ple comparisons. A P value <0.05 was considered significant. All statistical
analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.).
For further information regarding statistical analysis, see the section re-
garding xenograft studies above.
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